Prohibiting Tianeptine and Other Dangerous Products Act of 2026
- Bill Number
- H.R. 7407
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-05: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-02-26T18:18:14Z
AI-Generated Summary
Purpose
The legislation aims to strengthen regulations on dietary supplements by prohibiting the sale and distribution of products that do not qualify as legitimate dietary supplements or those produced with involvement from disqualified individuals. It targets unsafe or misrepresented products, such as tianeptine (a substance sometimes illegally marketed as a supplement despite its risks), to protect public health.
Key Provisions
- Prohibited Acts: Adds two new violations to Section 301 of the Federal Food, Drug, and Cosmetic Act (FD&C Act):
- It bans introducing or delivering into interstate commerce any product marketed as a dietary supplement that fails to meet the legal definition of a dietary supplement (under Section 201(ff), which requires supplements to be intended for ingestion and contain dietary ingredients like vitamins, minerals, herbs, or amino acids, excluding drugs or other non-qualifying items).
- It prohibits introducing or delivering dietary supplements that were prepared, packed, or held with the help of or under the direction of a person barred (debarred) from such activities under Section 306 of the FD&C Act (debarment typically applies to those who have violated food or drug laws).
- Import Restrictions: Updates Section 801(a) of the FD&C Act to allow exclusion of imported products violating these new rules, treating them similarly to other prohibited items.
- Seizure Powers: Expands Section 304 of the FD&C Act to enable the government to seize products that violate these provisions, including during import or domestic distribution.
Significant Changes to Existing Law
- Introduces specific prohibitions on mislabeled or non-qualifying dietary supplements, closing gaps in current law that may allow dangerous products (like tianeptine, which acts like an opioid and is not a true supplement) to enter the market.
- Extends debarment rules (previously more focused on drugs) to dietary supplements, preventing convicted or sanctioned individuals from participating in their production or handling.
- Enhances enforcement tools by linking these violations to import refusals and seizures, making it easier for regulators to remove non-compliant products from circulation.
Potential Impacts
- Government Agencies: The Food and Drug Administration (FDA) gains clearer authority to block imports, seize products, and pursue violations, potentially increasing enforcement workload but improving oversight of the $50+ billion dietary supplement industry.
- Citizens: Consumers benefit from reduced access to harmful or fraudulent supplements, lowering risks of adverse health effects (e.g., addiction or toxicity from substances like tianeptine); however, it may limit availability of some niche products if they are deemed non-compliant.
- International Relations: Could affect trade by leading to more refusals of imported supplements, prompting negotiations with exporting countries to align with U.S. standards, but no direct impact on broader diplomatic ties.
Main Stakeholders Affected
- Dietary Supplement Manufacturers and Sellers: Face stricter compliance requirements, potential seizures, and legal penalties for non-qualifying products or involvement of debarred persons.
- Consumers: Primarily protected, especially those seeking safe nutritional aids, but may experience higher prices or fewer options due to enhanced regulation.
- FDA and Regulators: Empowered with new tools, affecting their inspection, import screening, and enforcement priorities.
- Debarred Individuals: Restricted from supplement-related activities, limiting their business opportunities.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the FD&C Act's framework without altering core definitions, but expands prosecutorial scope under interstate commerce clauses; violations could lead to civil or criminal penalties (fines, injunctions, or imprisonment) as with other Section 301 prohibitions.
- Constitutional: Aligns with Congress's authority to regulate interstate commerce and protect public health under the Commerce Clause; no apparent free speech or due process issues, as it targets conduct (marketing and distribution) rather than expression.
- Political: Addresses growing concerns over supplement safety amid rising misuse of substances like tianeptine, potentially appealing to public health advocates; may spark debate between industry groups seeking lighter regulation and consumer safety proponents pushing for more oversight.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2026-02-05: Referred to the House Committee on Energy and Commerce.
- 2026-02-05: Introduced in House
- 2026-02-05: Introduced in House
Bill Versions
- Prohibiting Tianeptine and Other Dangerous Products Act of 2026 — issued 2026-02-05 — PDF (2 pages)